Filtered By:
Management: Government
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 334 results found since Jan 2013.
Biden ’s Real COVID-19 Challenge Is Restoring a Nation’s Trust in Science
“If the public-health professionals, if Dr. [Anthony] Fauci, if doctors tell us we should take it, I would be first in line. If Donald Trump tells us we should take it, then I’m not taking it.”
That was Vice President-elect Kamala Harris’ response when asked by the moderator of an Oct. 7 debate whether she would get vaccinated against COVID-19. It perfectly captured the politicization of the U.S. response to COVID-19 under the outgoing Trump Administration—and how dangerous that red and blue tinting of the pandemic response has been for the American public. Behaviors like wearing masks and soc...
Source: TIME: Health - November 7, 2020 Category: Consumer Health News Authors: Jamie Ducharme and Alice Park Tags: Uncategorized COVID-19 Source Type: news
The Critical Role of Prenatal Genetic Study in Prevention of Primary Immunodeficiency in High-risk Families: The Largest Report of 107 Cases.
This study aims to investigate the role of prenatal diagnosis (PND) in Iranian couples with a previous history of primary immunodeficiency disorders (PIDD) in their family. All referred couples with a family history of PIDD and a tendency for PND were included in this project. Based on gestational age, chorionic villus sampling (CVS) was performed to analyze the molecular defect of the fetus according to the previous gene defect of the affected case in the family. Postnatal confirmation was performed by immunological screening tests. In a total of 100 cases, CVS was not evaluated in 19 patients due to unwillingness (n=5),...
Source: Iranian Journal of Allergy, Asthma and Immunology - October 18, 2020 Category: Allergy & Immunology Authors: Modarresi SZ, Sabetkish N, Badalzadeh M, Tajik S, Esmaeili B, Fazlollahi MR, Houshmand M, Gharehdaghi J, Niroomanesh S, Rahimi Sherbaf F, Alizadeh Z, Khodayari Namini N, Maddah M, Pourpak Z, Moin M Tags: Iran J Allergy Asthma Immunol Source Type: research
UCLA draws record $1.4 billion in research funding
UCLA attracted record support for its wide-ranging research in the 2019 –20 fiscal year, receiving $1.427 billion in research funding.2020 is the third consecutive year that the university has topped its previous best. Research support has grown by 38% since 2015. UCLA now ranks sixth among all universities in total research expenditures.“This is a tribute to the great work being done across disciplines at UCLA,” said Roger Wakimoto, vice chancellor for research. “These funds help bring about major breakthroughs in medical science, advance knowledge in numerous other disciplines, strengthen our teaching, and suppor...
Source: UCLA Newsroom: Health Sciences - October 12, 2020 Category: Universities & Medical Training Source Type: news
The FDA Is Slowing Down COVID-19 Vaccine Approval. That Could Be Good for Public Health
New U.S. Food and Drug Administration (FDA) guidance means a COVID-19 vaccine likely will not be approved by Election Day—which could actually be a good thing for public health.
On Oct. 6, the agency posted an industry guidance document on its website asking pharmaceutical companies applying for emergency-use authorization of a COVID-19 vaccine to monitor study subjects for at least two months after vaccination, so they can look for side effects that may arise over time and get a better sense of the shot’s efficacy. That means it’s unlikely any manufacturer will receive authorization before Election Day o...
Source: TIME: Health - October 7, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Source Type: news
Johnson & Johnson ’ s Coronavirus Vaccine Enters Phase 3 Trial With Beth Israel
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p1").init({"mcp":"cbs","width":"100%","height":"100%","video":"4730668","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p1","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId":"sc_va","marketingCloudId":"823BA0335567497F7F000101@AdobeOrg","trackingServer":"cbsdigitalmedia.hb.omtrdc.net","customTrackingServer":"cbsdigitalmedia.d1.sc.omtrdc.net","chapterTracking":false,"version":"1.5"},"comscore":{"clientId"...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 23, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Beth Israel Deacones Medical Center Coronavirus Johnson & Johnson Source Type: news
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. These results have been submitted to medRxiv and are due to be published online imminentl...
Source: Johnson and Johnson - September 23, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins.
Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news
Cutaneous Radiation Injuries: Models, Assessment and Treatments.
This report provides an overview of information that was presented and the subsequent guided discussions.
PMID: 32857831 [PubMed - as supplied by publisher]
Source: Radiation Research - August 27, 2020 Category: Physics Authors: DiCarlo AL, Bandremer AC, Hollingsworth BA, Kasim S, Laniyonu A, Todd NF, Wang SJ, Wertheimer ER, Rios CI Tags: Radiat Res Source Type: research
FDA Issues Emergency Authorization For Convalescent Plasma To Treat Covid-19
(CNN) — The US Food and Drug Administration on Sunday issued an emergency use authorization for convalescent plasma to treat Covid-19, saying the “known and potential benefits of the product outweigh the known and potential risks of the product.”
The FDA said more than 70,000 patients had been treated with convalescent plasma, which is made using the blood of people who have recovered from coronavirus infections.
“Today I am pleased to make a truly historic announcement in our battle against the China virus that will save countless lives,” President Trump said at a White House briefing, referr...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 24, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Syndicated CBSN Boston CNN Coronavirus Source Type: news
Pharmacists Can Vaccinate Kids; Lockdowns Slash Vaccination Levels Pharmacists Can Vaccinate Kids; Lockdowns Slash Vaccination Levels
The US government said pharmacists would be allowed to administer routine vaccines to children, calling a drop in immunization rates during COVID-19 a"public health threat."Reuters Health Information
Source: Medscape Allergy Headlines - August 20, 2020 Category: Allergy & Immunology Tags: Pediatrics News Source Type: news
US to Make Coronavirus Strain for Possible Human Challenge Trials US to Make Coronavirus Strain for Possible Human Challenge Trials
US government scientists have begun efforts to manufacture a strain of the novel coronavirus that could be used in human challenge trials of vaccines, Reuters has learned.Reuters Health Information
Source: Medscape Allergy Headlines - August 17, 2020 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
Why the U.S. Is Losing the War On COVID-19
It is a frightening time to live in the United States. COVID-19, a novel disease as ruthless as it is seemingly random, is picking us off by the thousands; even many of those who “recover” may never truly be the same again. The pandemic has exposed the gulf between what this country promises for its citizens and what it actually delivers. And as the U.S. barrels toward Election Day, the outbreak is sure to complicate the voting process, with potentially disastrous results.
For a short time in the spring, it appeared the U.S. was getting a grip on its outbreak. Hard-hit states like New York successfully flattene...
Source: TIME: Science - August 13, 2020 Category: Science Authors: Alex Fitzpatrick Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news
U.S. Government to Launch ' Overwhelming ' COVID-19 Vaccine Campaign by November U.S. Government to Launch ' Overwhelming ' COVID-19 Vaccine Campaign by November
The US government anticipates launching a promotions campaign by November to encourage Americans to get vaccinated against COVID, contingent on evidence that a vaccine will be available by year ' s end.Reuters Health Information
Source: Medscape Allergy Headlines - August 3, 2020 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
US to Pay $2.1 Bln to Sanofi, GSK, in COVID-19 Vaccine Deal US to Pay $2.1 Bln to Sanofi, GSK, in COVID-19 Vaccine Deal
The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers ' testing and manufacturing.Reuters Health Information
Source: Medscape Allergy Headlines - August 3, 2020 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
